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The role of NK cells against HIV-1 infections remains to be elucidated in vivo. While humanized mouse models potentially
could be used to directly evaluate human NK cell responses during HIV-1 infection, improved functional development of
human NK cells in these hosts is needed. Here, we report the humanized MISTRG-6-15 mouse model, in which NK cells
were quick to expand and exhibit degranulation, cytotoxicity, and proinflammatory cytokine production in nonlymphoid
organs upon HIV-1 infection but had reduced functionality in lymphoid organs. Although HIV-1 infection induced functional
impairment of NK cells, antiretroviral therapy reinvigorated NK cells in response to HIV-1 rebound after analytic treatment
interruption. Moreover, a broadly neutralizing antibody, PGT121, enhanced NK cell function in vivo, consistent with
antibody-dependent cellular cytotoxicity. Monoclonal antibody depletion of NK cells resulted in higher viral loads in multiple
nonlymphoid organs. Overall, our results in humanized MISTRG-6-15 mice demonstrated that NK cells provided direct anti–
HIV-1 responses in vivo but were limited in their responses in lymphoid organs.

Introduction

NK cells recognize ligands presented on the surface of HIV-1–
infected cells, including infection-induced self-proteins (1, 2) and
possibly the viral envelope protein (3), as well as Fc regions of
viral-specific antibodies (4, 5) and MHC class I molecules (6, 7) that
engage activating or inhibitory NK receptors, respectively. Genetic and epidemiological studies strongly support an active role for
NK cells in HIV-1 infection. Interestingly, the combined genotype
of certain germline-encoded killer immunoglobulin-like receptors
(KIRs) — generally selectively expressed on NK cells — and their
HLA ligands are associated with slower HIV-1 disease progression
(8, 9) or protection against HIV-1 acquisition (10–12). KIR-dependent NK cell activities appear to directly mediate immune pressure
leading to HIV-1 evolution in infected individuals (13). In addition, antibody-dependent cellular cytotoxicity (ADCC), potentially mediated by NK cells, is associated with HIV-1 control (14–17)
and is linked to vaccine-induced protective immunity against HIV
infection (18–20). NK cells can inhibit HIV replication but these
studies have been limited to in vitro and ex vivo studies on NK cells
from peripheral blood samples (21–25). Thus, the in vivo role of NK
cells in direct control of HIV-1 infections has not been elucidated.
In mouse experimental models, NK cells have disparate effector functions across tissues, and tissue-resident NK cells acquire
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unique functions different from blood NK cells for viral containment (26, 27). In humans, evidence for discrete stages of differentiation and functional development of blood and tissue NK
cells has also been reported. While most NK cells in the blood are
mature (CD56dimCD16+) with a strong capacity to lyse target cells,
the immature and noncytolytic CD56brightCD16 – NK cells are the
predominant subset in secondary lymphoid tissues (28–30), which
are the major sites for HIV-1 infection in untreated individuals (31–
33) and the most important anatomical reservoirs for latent HIV-1
in people on suppressive antiretroviral therapy (ART) (34). However, there is a relative scarcity of studies assessing the pleiotropic
functions of tissue NK cells during HIV-1 infection due to a lack
of easy-access tissue samples. Therefore, how NK cells influence
HIV-1 infection in vivo remains unknown, despite strong evidence
from epidemiological and in vitro studies.
Generation of human immune system mice (humanized
mice) can be achieved in various strains of immunodeficient mice
transplanted with human hematopoietic stem and progenitor
cells. Humanized mice are useful tools to study HIV-1 infection
and immune responses (35) but human NK cells reconstituted in
immunodeficient mice are numerically and functionally deficient,
secrete lower levels of IFN-γ and do not respond to NK cell–susceptible targets (36, 37). This may be due to the lack of cross reactivity
between murine IL-15 and human IL-15 receptors, since IL-15 is
essential for the development and survival of NK cells and human
IL-15 injection can rescue differentiation of human NK cells (38,
39). However, IL-15 supplementation is only temporary, and the
appropriate distribution of IL-15–expressing cells that is critical for
development and maintenance of NK cells with circulating or tissue-resident identities (40) cannot be achieved through cytokine
injection or transgenic expression. Both hematopoietic and nonhematopoietic cells provide IL-15 and IL-15 receptor α (IL-15Rα)
1
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Figure 1. Improved human NK cell reconstitution
and functionality in humanized MISTRG-6-15
versus NSG mice. (A) Representative flow cytometry
plots of NKp46+ and CD14+ cells in blood between
MISTRG-6-15 and NSG mice. (B) Percentage of CD3+,
CD14+, and NKp46+ cells in blood. Cells were gated
on human CD45+ population. (C) Percentage of
CD3–CD56+ NK cells (defined by CD56 and not NKp46,
to reduce inclusion of group 1 and 3 innate lymphoid
cells) in spleen, liver, lung, and LN. Cells were gated
on human CD45+ population. (D–F) Percentage of
CD107a+, GZMB+, IFNγ+, and TNFα+ NK cells in spleen
(D), liver (E), lung (F), and LN (G) after 4 hours of
ex vivo stimulation with PMA/ionomycin. Data
displayed as mean ± SEM. 8 mice per group. P values
were calculated using 2-way ANOVA with Šidák’s
multiple comparison test. **P < 0.01, ***P < 0.001,
and ****P < 0.0001.

and both can drive NK cell differentiation with hematopoieticderived IL-15Rα being more important to the late maturation
process (41). MISTRG mice with knock-in expression of human
M-CSF, IL-3/GM-CSF, SIRPα, and THPO that together support
efficient development of human myeloid cells — the hematopoietic source of IL-15 — showed improved development of human
NK cells in tissues (42). Since human IL-15 production in the MISTRG model is solely dependent on human myeloid cells, experimental conditions that destroy the myeloid cell compartment,
such as clodronate or HIV-1 infection, lead to rapid loss of NK
cells (42, 43). On the other hand, a mouse with human IL15 and
signal regulatory protein α (SIRPA) knockin, named SRG-15, can
provide human IL-15 from the nonhematopoietic compartment
comprising murine stromal cells and epithelial cells, as it does not
support efficient human myelopoiesis (40). SRG-15 mice promote
improved human NK cell maturation in the bone marrow and
periphery, which rely on the suboptimal cross-reactivity between
human IL-15 and murine IL-15RA (44). To further improve NK cell
development, we generated MISTRG mice with humanized IL-6
and IL-15, termed MISTRG-6-15, which produce human IL-15
from both hematopoietic and nonhematopoietic cell compartments, which is more physiologically relevant than the MISTRG
and SRG-15 models. Since IL-6 stimulates hematopoietic progenitor cells and myeloid differentiation in mice (45), IL-6 humanization partially blocks murine hematopoiesis to better support
overall reconstitution of multiple lineages of human immune cells.
Here, we characterized human NK cell development and its
functional dynamics during acute and chronic HIV-1 infection
or after ART in humanized MISTRG-6-15 mice. More impor2

tantly, we showed that NK cell depletion led to increased HIV-1
replication and accelerated disease progression in vivo. Thus, we
provide direct evidence that human NK cells can control HIV-1
infection in vivo.

Results

Functional development of human NK cells in humanized MISTRG6-15 mice. We first compared reconstitution and functionality of
human NK cells in reconstituted MISTRG-6-15 and the commonly
used NSG mice. MISTRG-6-15 mice had significantly more circulating NK cells and monocytes compared with NSG mice engrafted with the same cord blood sample (Figure 1, A and B). In addition, tissue NK cells — which are defined by CD56 and not NKp46
to reduce the inclusion of group 1 and 3 innate lymphoid cells
— were also significantly higher in MISTRG-6-15 mice (Figure
1C and Supplemental Figure 1; supplemental material available
online with this article; https://doi.org/10.1172/JCI162694DS1).
Furthermore, NK cells in all tissues of the MISTRG-6-15 mice produced more cytokines (Figure 1, D–G) and had stronger cytolytic
capacity (Supplemental Figure 2A) than those in NSG mice. Concanamycin A was used to confirm that the killing of K562 cells was
perforin dependent (Supplemental Figure 2B). Thus, human NK
cells show improved reconstitution in both number and function
in MISTRG-6-15 mice compared with NSG mice.
Human NK cell functions vary widely across tissues, particularly with respect to lymphoid NK cells. Indeed, the frequency
of NK cells in lymph nodes (LNs) of MISTRG-6-15 mice was low,
and the vast majority of LN NK cells (over 90%) were functionally immature (Figure 1G) compared with NK cells in the spleen,
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Figure 2. Lymphoid tissue NK cells isolated from healthy human donors are functionally defective against HIV-1–infected cells. (A–E) NK cells from
human blood and tonsils were gated on CD3–CD56+ population. (A) Representative flow cytometry plots of CD56 and CD16 expression of human blood and
tonsil NK cells. (B) Percentage of CD16+ NK cells in blood (n = 13) and tonsil (n = 5). (C) Percentage of Perforin+ or GZMB+ NK cells in blood and tonsil after
4 hours of PMA/ionomycin stimulation. (D and E) Percentage of killing of K562 (D) and HIV-1 infected CD4+ T cells (E) after coculture for 4 hours at 1:1 effector-to-target ratio (E:T). Symbols represent biologically independent samples isolated from blood (n = 5) and tonsils (n = 3) from healthy donors. (F–H) in
humanized MISTRG-6-15 mice, percentage of (F) CD16+ NK cells (n = 5), (G) GZMB+ NK cells (n = 3), and (H) K562 killing (n = 5) by NK cells in the blood, lung,
liver, spleen, and LN after ex vivo culture for 4 hours with K562 targets at 1:1 E:T. Data displayed as mean ± SEM. In B–E, P values were calculated using
unpaired, 2-tailed t tests. In F–H, P values were calculated using 1-way ANOVA with Tukey’s multiple comparison post test. **P < 0.01, ***P < 0.001, and
****P < 0.0001.

liver, and lung (Figure 1, D–F). To further compare functions of
lymphoid NK cells from humans and MISTRG-6-15 mice, we
purified NK cells from human tonsil and blood samples. Similar
to previous studies (28–30), we found that the frequency of NK
cells expressing CD16, granzyme B (GZMB), or perforin was significantly higher in blood compared with tonsil (Figure 2, A–C),
and tonsil NK cells could not lyse K562 cells (Figure 2D) or autologous CD4+ T cells infected by HIV-1 (Figure 2E). The predominance of immature NK cells in lymphoid tissues is likely due to
their expression of the homing receptor CCR7, which was virtually
absent in mature CD16+ NK cells (Supplemental Figure 3). To evaluate the ADCC activity, we cocultured blood and tonsil NK cells
with autologous CD4+ T cells infected with a recombinant HIV-1
reporter virus (HIVivo-HA) (Supplemental Figure 4). The humanized IgG1 anti-HA antibody could bind to HIVivo-HA infected
cells but had no neutralizing activity (46). Blood NK cells were
able to lyse more than 40% of the infected autologous blood CD4+
T cells in a Fc-dependent manner, as evidenced by the complete
loss of cell lysis when treated with a mutant anti-HA antibody carrying mutations (GRLR) that abrogated binding to activating Fc
receptors. In contrast, tonsil NK cells exhibited minimal cytolysis of the autologous tonsil CD4+ T cells regardless of treatment,
similar to controls without antibody. Similar to the disparate tissue
distribution patterns in humans, the vast majority of NK cells in
blood and nonlymphoid tissues of MISTRG-6-15 mice exhibited
mature phenotypes with CD16 expression (Figure 2F and Supple-

mental Figure 5). By contrast, the dominant presence of CD16 –
immature NK cells was observed in LNs of MISTRG-6-15 mice
(Figure 2F). These NK cells produced very low levels of effector
molecules (Figure 2G) and were unable to kill K562 cells (Figure
2H). Overall, the functional development of human NK cells in
MISTRG-6-15 mice with tissue-specific disparities comparable to
humans allowed us to compare tissue-specific NK cell responses
with HIV-1 infection.
Dynamics of NK cell responses in MISTRG-6-15 mice during acute
and chronic HIV-1 infection. We infected MISTRG-6-15 with HIV-1BaL
strain to characterize viral infection. Plasma HIV-1 RNA was readily
detectable as early as 7–8 days after infection and peaked around 3
weeks (Figure 3A). Viral replication was paralleled by CD4+ T cell
depletion in blood and tissues (Figure 3, B and C). Viral infection
was detected by cell-associated HIV-1 RNA (cavRNA) quantification in various tissues of infected mice, showing clear viral dissemination (Supplemental Figure 6A). Levels of CD16 expression and
functions of NK cells in blood, lymphoid and nonlymphoid tissue
were enhanced during acute infection, albeit the enhancement in
lymphoid tissues was less robust (Figure 3, D and E, and Supplemental Figure 6B). CD8+ T cells exhibited similar functional patterns with reduced degranulation and proinflammatory cytokine
production in the LNs (Supplemental Figure 7). Previous studies
showed that several immune checkpoint receptors (ICRs) were
upregulated in NK cells in the setting of cancer or chronic viral
infection and that these receptors negatively regulated NK cell
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Figure 3. Human NK cells respond
to HIV-1 infection in humanized
MISTRG-6-15 mice. MISTRG-6-15
mice were infected with HIV-1BAL. (A)
Longitudinal viral load measurement (n = 8). Lines connect data
from the same mice. For analysis in
B–F, blood and tissue samples were
collected on day 21 after infection.
(B and C) Percent CD4+ of total T
cells in blood (B) (n = 15) or tissues
(C) (n = 6) of uninfected and infected
MISTRG-6-15 mice. Cells were gated
on human CD45+CD3+ population.
(D) Percentage of blood and tissue
NK cells positive for CD16. (E) Percentage of tissue NK cells positive
for CD107a, GZMB, IFN-γ, and TNF-α
after ex vivo stimulation with PMA/
ionomycin for 4 hours. In D and E, 5
mice were used per group. (F) Percentage of tissue NK cells positive
for KLRG1, LAG3, PD-1, TIGIT, and
TIM3. In D and E, 5 mice were used
per group. In F, 4 mice were used
per group. Data displayed as mean
± SEM. In B and C, P values were
calculated using unpaired, 2-tailed
t tests. In E and F, P values were
calculated using 2-way ANOVA with
Šidák’s multiple comparison test.
*P < 0.05,**P < 0.01, ***P < 0.001,
and ****P < 0.0001.

cytotoxicity (47–50). Similarly, we found rapid increases of KLRG1,
LAG-3, PD-1, and TIGIT expression in blood and tissue NK cells
within 2 weeks after HIV-1 infection (Figure 3F and Supplemental
Figure 6C). ICR upregulation in CD8+ T cells was also observed
in the same groups of mice 21 days after HIV-1 infection (Supplemental Figure 8). Although NK cells were more functionally active
during acute infection, upregulation of ICRs might lead to functional impairment. To further evaluate the possibility of functional
impairment in NK cells during the course of HIV infection (Figure
4A), we monitored the survival, proliferation, and functionality of
NK cells from day 0 to day 168 after infection. Rapid expansion of
NK cells was seen in all organs (Figure 4B). A slow decline in NK
numbers was seen between day 42 and 168. Correspondingly, NK
cells proliferated in the organs early during the course of infection
and returned to baseline when the infection was sustained beyond
100 days (Figure 4C). After ex vivo stimulation with PMA/ionomycin, NK cells at an early stage of infection showed increased potency for degranulation and IFN-γ and GZMB production, which then
declined during the chronic phase (Figure 4, D–F). Notably, without
ex vivo stimulation, the baseline functions of NK cells from acutely and chronically infected mice were similar and were higher than
those from uninfected mice (Supplemental Figure 9), suggesting
continuous NK cell activation. Taken together, these results suggest
that HIV-1 results in chronic activation and functional impairment
of NK cells in all tissues.
Liver NK cells had the highest percentage degranulation and
cytokine production when compared with NK cells in other organs,
4

but NK cells in all organs showed increased functionality after HIV
infection that persisted throughout the studied span of disease.
Additionally, the liver NK cells had the least decline in functionality throughout the course of infection when compared with the
other organs. These data suggest that liver NK cells retained their
functionality throughout the course of infection, possibly through
the establishment of immunological memory in the liver (3, 51).
ART prevents the progressive loss of NK cell functionality. In people living with HIV-1, functional impairment of NK cells due to
chronic HIV-1 infection can be partially restored by ART (52–54).
In the MISTRG6-15 mouse model, the expansion and functional
activation of NK cells occurred within the first 10 days of infection, whereas NK cell numbers and functions began to decline on
day 50 and almost returned to baseline after day 100 (Figure 4).
Notably, the levels of inhibitory receptors including LAG3, PD-1,
and TIGIT in NK cells increased during acute infection (Figure
3F), suggesting that early ART initiation may better improve NK
cell functional restoration. To test this hypothesis, we studied
mice that were initially infected for 4 weeks and then compared
NK cells in mice on ART for 8 weeks to those from untreated mice
(Figure 5A). The levels of inhibitory receptors including LAG-3,
PD-1, and TIGIT all increased on NK cells after infection and were
partially reduced in mice receiving ART (Figure 5, B–D). Next,
we performed analytic treatment interruption (ATI) to determine
whether NK cell functions were preserved by ART. Mice under
ART had undetectable viral load, and virus rebounded in all animals within 4 weeks after ATI (Figure 5E). We found that the num-
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Figure 4. NK cell expansion and
increased functionality during
the course of HIV-1 infection
wanes with time. MISTRG-6-15
mice were infected with HIV-1BAL.
On days 0, 10, 21, 42, 56, 112, and
168 after infection, 4–6 mice at
each time point were euthanized
for blood and tissue collection.
(A) Plasma HIV-1 RNA levels;
red line illustrates the average.
(B) Number of human NK cells
(huCD45+CD3–CD56+) throughout the course of infection in
spleen, liver, lung, and LN. (C–F)
Ki67, CD107a, IFN-γ, and GZMB
expression by NK cells in blood,
spleen, liver, lung, and LN. NK
cells purified from tissues were
stimulated with PMA/ionomycin ex vivo for 4 hours before
flow cytometry analysis. Data
displayed as mean ± SEM.

ber of NK cells in various tissues increased following ATI (Figure
5F). In addition, NK cell functions including cytokine production
and cytotoxicity were also increased after ATI (Figure 5, G–K).
Notably, LN NK cells responded to initial infection (Figure 3) but
did not respond to viral rebound after ATI, suggesting that additional approaches might be needed for the functional restoration
of LN NK cells. Nonetheless, for nonlymphoid NK cells, these
results suggest that ART prevented their functional impairment —
including the loss of proliferation capacity and degranulation seen
in chronically infected mice (Figure 4) — and ART reinvigorated
NK cells in response to HIV-1 rebound after ATI.
NK cells suppress HIV-1 infection in vivo. Previous studies
showed that transfusion of human blood NK cells suppressed
HIV infection in humanized mice (55, 56). While our studies
here show NK cells responded to HIV-1 infection as well as viral
rebound after ATI, it is unclear whether endogenous NK cells can
directly impact HIV-1 replication in vivo. To address this, we first
isolated NK cells from various organs of infected mice and cocultured them with HIV-infected donor-matched CD4+ T cells for 4
hours. NK cells from all of the organs did exhibit degranulation
and killed HIV-1–infected target cells, but liver NK cells showed
the most pronounced response (Figure 6, A and B). Next, the in
vivo control of HIV-1 by NK cells was studied by depleting NK
cells with a monoclonal antibody against NKp46 that has been

shown to deplete human NK cells in humanized mice (57). Here,
depletion of NK cells was successful in all studied organs (Figure
6, C and D). On day 14 after HIV-1 infection CD4:CD8 ratios were
significantly lower upon NK cell depletion compared with non-NK
cell depleted mice, wit the exception of the LNs (Figure 6E). No
apparent CD4 depletion was observed in LNs, even in the control
mice, which is likely due to the small number of CD4+ T cells that
express CCR5 (Supplemental Figure 10). Next, we collected blood
and tissues to measure plasma HIV-1 RNA and cell-associated
HIV-1 RNA, respectively. NK depletion led to an increase in plasma HIV-1 RNA by 5–10 fold (Figure 6F). Depletion of NK cells also
caused increased cell-associated viral RNA in tissues, especially in
the liver (Figure 6G), which was consistent with the robust NK cell
response in the liver. These results strongly suggest that NK cells
directly suppress HIV-1 replication in vivo.
Antibody treatment improves NK cell functionality. Administration of broadly neutralizing antibodies (bNab) into viremic individuals enhances viral-specific T cell responses (58–62) and may
also modulate NK cell functions through Fc-dependent mechanisms. To address the potential role that bNab therapy may have
on NK responses, we used the HIV-neutralizing antibody PGT121
(63) to understand the Fc-dependent NK cell functions. Although
IgM+ or IgD+ human B cells develop properly in most humanized mice, a scarce amount of hypermutated, class-switched
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Figure 5. ART restores NK cell
responses during HIV-1 infection.
MISTRG-6-15 mice were infected
with HIV-1BAL. (A) Infection and
treatment scheme for the uninfected (white), untreated (red), and
ART (blue) groups. Copies of plasma HIV-1 RNA were measured by
RT-qPCR for the untreated and ART
groups. (B–D) Percentage of tissue
NK cells positive for KLRG1, LAG3,
PD-1, and TIGIT. (E) viral load measurement after ATI. Lines connect
data from the same mice. (F) Number of CD3–CD56+ NK cells in spleen,
liver, lung, and LN 4 weeks after
ATI. (G–K) Percentage of CD107a+,
GZMB+, IFN-γ+, and TNF-α+ NK
cells in indicated tissues. NK cells
purified from tissues were stimulated with PMA/ionomycin ex vivo
for 4 hours before flow cytometry
analysis. Data displayed as mean ±
SEM. In B–K, 4 mice were used for
each time point. In B–D and F–K, P
values were calculated using 2-way
ANOVA with Šidák’s multiple comparison test. *P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001.

IgG antibodies are produced, mainly due to the lack of germinal
center response (64), necessitating a passive antibody treatment
approach to study ADCC by NK cells. Moreover, we also used
PGT12 with GRLR mutations that block antibody binding to Fc
receptors (46). PGT121 or PGT121GRLR was injected into infected
mice, and viral loads in the plasma were reduced by both antibodies (Figure 7, A and B). In mice treated with PGT121, the spleen
and lung had greater reduction of cavRNA and numbers of infected cells than the PGT121GRLR group (Figure 7, C and D), indicating Fc-dependent clearance of HIV-1–infected cells. No reduction
was seen in the LNs, likely due to the lack of functionally mature
NK cells in the LNs. Surprisingly, the number of HIV-p24+ cells in
the liver was reduced by PGT121, whereas liver HIV-1 RNA was
unchanged. It is possible that HIV-1 RNA signals were detected
from kupffer cells that engulfed HIV-1–infected T cells upon antibody treatment. Since the GRLR mutation abolishes both ADCC
(Supplemental Figure 4) and ADCP (46), it is possible that macro6

phages and NK cells both contributed to the clearance of HIV-1–
infected cells mediated by PGT121 interacting with the intact Fc
fragment. Next, we aimed to evaluate the influence of antibody
therapy on NK cells. NK cell functions such as degranulation and
GzmB production were selectively enhanced by PGT121 in the
spleen, liver, and lung, and were slightly enhanced in the lymph
nodes. By contrast, the PGT121GRLR did not have any effect on NK
cell functionality (Figure 7E). These results support the hypothesis that antibody therapies improve NK cell cytolytic activity in an
Fc-dependent manner.

Discussion

Despite strong epidemiological evidence from large-scale
cross-sectional studies, there is still a nascent understanding of
the roles that NK cells play in HIV-1 infection in humans. The
lack of clarity is likely due to several factors: the dependence of
NK cell function on the associated HLA genotype, the functional
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Figure 6. NK cells exhibit direct antiHIV-1 control in vivo. MISTRG-6-15 mice
were infected with HIV-1BAL. (A and B)
NK cell degranulation and target cell
killing. CD4+ T cells were purified from
uninfected mice and then infected with
HIV-1 reporter virus NL4-3-ΔEnv-EGFP.
Autologous NK cells were purified from
indicated tissues from infected mice
and then cocultured with infected CD4+
T cells for 4 hours at indicated effector-to-target ratio. (A) NK cell degranulation and (B) live/dead staining of
HIV-1–infected target cells (GFP+) was
determined by flow cytometry. Cells
were purified from 3 mice. (C and D) NK
depletion by αNKp46 antibodies. Percentage of CD3–CD56+ NK cells in mouse
tissues with or without αNKp46 antibody
treatment. (E) CD4:CD8 ratio with or
without αNKp46 antibody treatment. (F
and G) Copies of plasma HIV-1 RNA (F)
and copies of cavRNA in tissues (G) with
or without αNKp46 antibody treatment.
Data displayed as mean ± SEM. 5 mice
were used in the isotype-treated group
and 4 in the αNKp46-treated group. In
(B) P values were calculated using 1-way
ANOVA with Tukey’s multiple comparison post test. In (D, E, and G) P values
were calculated using 2-way ANOVA with
Šidák’s multiple comparison test. In F,
P value was calculated using unpaired,
2-tailed t test. *P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001.

diversity not fully captured by examination of circulating NK cells,
and finally, the inadequacy of animal models. The MISTRG-6-15
mouse model recapitulates the human immune system beyond
earlier humanized mouse models. Of note, the NK population is
robust and more functional than it is in NSG mice, and it better
mirrors human NK responses to immunological challenges in the
various organs. More importantly, the various organs also showed
dramatically different responses and functionality of the NK cells,
especially when comparing lymphoid and nonlymphoid tissues.
While NK cells from lymphoid tissues from human donors had
reduced functionality when compared with blood, human NK
cells in MISTRG-6-15 mice had similar properties. Thus, human
NK cells in reconstituted MISTRG-6-15 mice more closely resembled NK cells in humans than prior humanized mouse models.
Here, we further showed that, in humanized MISTRG-6-15 mice
infected with HIV-1, the depletion of NK cells by monoclonal antibody resulted in higher levels of viral replication and accelerated
loss of CD4+ T cells. For the first time, we found the direct evidence for control of HIV-1 infection by NK cells in vivo. Furthermore, we found no change in disease progression in the LNs after
NK depletion, consistent with the reduced functionality of human
NK cells in lymphoid tissue. Thus, this mouse model allows us to
study NK responses to HIV-1, especially in different organs and
lymphoid versus nonlymphoid tissues.

The humanized MISTRG-6-15 mice also allowed investigation of how bNab therapy modulates NK cell functions, as related
to antibody effector functions. In HIV-1–infected mice, NK cell
functionality was improved with PGT121 administration in all
organs, but was least improved in the lymph nodes. These results
highlight the potential difficulty in eliminating the remaining
infected cells in lymphoid tissues by bNabs, perhaps due to the
lack of functional effector cells.
During acute HIV-1 infection in humanized MISTRG-6-15
mice, NK cells rapidly expanded, and greater percentages of cells
degranulated and produced inflammatory cytokines in nonlymphoid tissues, while those in lymphoid tissues were immature or
dysfunctional throughout the course of infection. This was consistent with results in humans and studies of nonhuman primates
infected with SIV (65). This highlights a key concern of HIV-1 persistence in lymphoid tissue (34, 66, 67), as overall, the NK cells
appear to be less cytotoxic and proinflammatory. In chronically
infected mice, the functions of NK cells declined in various tested organs, which was accompanied by an increase in potential NK
exhaustion markers in all of the organs studied, which may allude
to overall dampened response to HIV-1 by these cells over time.
The dampened response was partially reduced after ART, which
resulted in the return of functional NK cells after treatment interruption. It is notable that NK cells in the LNs were not strongly
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Figure 7. PGT121 antibody-mediated viral
suppression enhances NK cell functionality. MISTRG-6-15 mice were infected with
HIV-1BAL. 2 doses (20 mg/kg) of PGT121
(n = 9), PGT121GRLR (n = 5), or PBS (n = 10)
were administered on days 14 and 17 after
infection. Blood samples were collected on
days 14 and 20. Tissues were collected on
day 20. (A) Plasma viral load before and
after antibody treatment. Lines connect
individual mice. P values were calculated
using 2-way ANOVA with Šidák’s multiple
comparison test. (B) Plasma viral load fold
change from day 14 to day 20. P values
were calculated using 1-way ANOVA with
Tukey’s multiple comparison post test.
(C) Copies of cavRNA in spleen, lung, and
LN. (D) Percentage p24+ of CD3+CD8– cells
in spleen, lung, and LN. (E) Expression of
CD107a or GZMB in NK cells in the spleen,
lung, and LN. NK cells purified from tissues were stimulated with PMA/ionomycin ex vivo for 4 hours before flow cytometry analysis. PGT121 (n = 3), PGT121GRLR
(n = 4), and PBS (n = 3). Data displayed as
mean ± SEM. In (C–E) P values for each
tissue were calculated using 2-way ANOVA
with Tukey’s multiple comparison post
test. *P < 0.05, **P < 0.01, ***P < 0.001,
and ****P < 0.0001.

affected by ART; this suggests that either (a) overall, NK cells minimally responded to HIV-1 in the lymphoid tissue initially or (b)
immunological stimulation was continuous due to the persistence
of HIV-1–infected cells in the lymphoid tissues despite ART (68).
By better understanding the role of NK cells during the course
of HIV-1 infection in different organs, more targeted therapies
and approaches to treatment can be pursued. Therefore, going
forward, it will be important to use this humanized mouse model
to dissect the molecular and cellular mechanism for NK cell-mediated HIV-1 suppression and to develop new strategies to enhance
NK cell functions, especially in the lymphoid tissues.

Methods

Mouse strains. The generation of knock-in mice encoding human
M-CSF, IL3/GM-CSF, SIRPA, THPO, IL6, and IL15 in a 129xBALB/c
(N3) genetic background (42, 44) was performed using Velocigene
technology (Regeneron Pharmaceuticals). Mice were bred to a Rag2−/−
Il2rg−/− background with homozygous human gene knock in (h/h) to generate 2 mouse colonies, including MCSFh/h GMCSFh/h IL3h/h THPOh/h
IL6h/h Rag2−/− Il2rgnull and MCSFh/h GMCSFh/h IL3h/h SIRPAh/h THPOh/h
IL6h/h IL15h/h Rag2−/− Il2rgnull. To produce mice for engraftment with
human cord blood CD34+ cells, the 2 colonies were crossed to generate
MCSFh/h IL3h/hGMCSFh/h SIRPAh/m THPOh/h IL6h/h IL15h/m Rag2−/− Il2rg−/−
mice (where h/m indicates human/mouse heterozygous gene knockin),
8

labeled MISTRG-6-15. Human SIRPA and IL15 loci were used as heterozygotes for engraftment throughout the study. Nonobese diabetic SCID
Il2rgnull (NSG) mice were obtained from The Jackson Laboratory.
Human samples. Deidentified human cord blood samples were
collected at the St. Louis Cord blood bank. Anonymous peripheral
blood samples were acquired from the Mississippi Valley Regional
Blood Center as waste cellular products. Human tonsils were collected
from elective tonsillectomies from Children’s Hospital in Saint Louis,
which were provided as surgical waste, with no identifiers attached.
Plasmids, monoclonal antibodies, and viruses. The anti-HA and
anti-HA-GRLR IgG1 heavy chain- and light chain- expressing plasmids as well as the HIVivo-HA viral plasmid were obtained from
Michel Nussenzweig laboratory at The Rockefeller University (New
York, New York, USA) (46). Codon optimized PGT121 heavy chain
and light chain expressing plasmids were obtained from Dennis
Burton laboratory at The Scripps Research Institute (La Jolla, California, USA). GRLR mutations were introduced to the PGT121 heavy
chain plasmid. PGT121 and anti-HA antibodies were produced
by transfecting the FreeStyle 293-F cells. Replication-competent
HIVBaL viruses were prepared from PHA-stimulated, CD8-depleted,
healthy-donor PBMCs. The HIV-1 reporter virus NL4-3-ΔEnv-EGFP
(AIDs reagent program) pseudotyped with VSVG envelope was prepared from transient transfection of plasmid DNA into 293T cells.
HIVivo-HA virus was also prepared from transient transfection of

J Clin Invest. 2022;132(24):e162694 https://doi.org/10.1172/JCI162694

RESEARCH ARTICLE

The Journal of Clinical Investigation  
293T cells. Concentrated viral stocks were prepared using Lenti-X
Concentrator (TaKaRa).
In vitro ADCC assay. Deidentified frozen tonsillar and blood
mononuclear cells were used for the functional analyses. To obtain
purified human NK cells from blood and tonsil mononuclear cells,
CD3/CD19 depletion was performed before NK cell purification
using EasySep Human NK Cell Isolation Kit (Stemcell Technologies).
Human CD4+ T cells were isolated using MojoSort Human CD4 T Cell
Isolation Kit (Biolegend). Purified CD4+ T cells were costimulated
with plate-bound CD3 (Biolegend, 300465) and soluble CD28 (Biolegend, 302943) antibodies with the presence of 20 ng/mL IL-2 (Biolegend, 589106) for 3 days prior to viral infection. Activated CD4+ cells
were infected with HIVivo-HA virus by spin inoculation at 1,200g for
2 hours at 30°C and incubated at 37°C in RPMI1640 medium (GIBCO)
containing 10% FBS supplemented with 20 ng/mL IL-2. Four days
after infection, infected tonsillar or blood CD4+ T cells were cocultured with their autologous NK cells in a 1:1 effector:target ratio with
anti-HA or anti-HAGRLR (1 μg/mL) antibody for 4 hours. Target cell lysis
was determined by the percentage of lysed infected cells (CD3+CD8–
HA+7-AAD+) in the total infected cells (CD3+CD8–HA+).
Generation of humanized mice. Human CD34+ cells were isolated
from cord blood using EasySep Human Cord Blood CD34 Positive
Selection Kit II (Stemcell Technologies) and were cryopreserved in
IMDM containing 7.5% DMSO. For MISTRG-6-15 mice, 1–3 day-old
newborn mice were humanized through injection of 1.5–3×104 cord
blood CD34+ cells intrahepatically. For NSG mice, 1–3 day-old newborn mice preconditioned with sublethal irradiation (80 cGy) followed
by intrahepatic injection of 1×105 cord blood CD34+ cells. Reconstitution of human CD45+ cells in blood was determined 9–10 weeks after
engraftment. Mice were grouped after checking for blood engraftment
to ensure that animals from different treatment groups or time points
had similar levels of human T cells, NK cells, and macrophages. In each
treatment group and at any time point, both male and female mice were
used. Mice were randomly sorted into different treatment groups and
time points. Identical cord blood donors were used when possible for
experiments, but variation in donors between experiments does exist.
HIV-1 infection and treatment of humanized mice. Nine to 10 weeks
after engraftment, the MISTRG-6-15 mice were infected with HIV-1BAL
(10 ng p24) by retroorbital injection. Uninfected mice received 100 μl
PBS by retroorbital injection. To quantify HIV-1 infection in tissues
by flow cytometry, intracellular HIV-p24 staining (Beckman Coulter)
was performed using the Cytofix/Cytoperm kit (BD Biosciences). To
quantify plasma HIV-1 RNA, blood samples were collected by retroorbital or submandibular bleeding. Plasma viral RNA was extracted by
Quick-RNA Viral Kits (Zymo Research) before reverse transcription
using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). Quantification of tissue HIV-1 RNA was described previously
(69). Briefly, after single cell suspensions of tissues were obtained
as described below, a fixed portion of each tissue was used for RNA
extraction by Direct-zol RNA Kits (Zymo Research), then reverse transcribed into cDNA using SuperScript III reverse transcriptase (Invitrogen). The HIV-1 gag-based qPCR assays using 10-fold serial dilutions
of HIV-1 genomic DNA as standard (70) were used to quantify plasmaand tissue-HIV-1 RNA. Total HIV-1 copy numbers were then obtained
by multiplying by the proportion of the total sample used for analysis.
To suppress HIV-1 replication in mice, antiretrovirals were added
into mouse food as previously described (71). Briefly, final concentra-

tions of drugs in mouse food are 1 g/kg tenofovir disoproxil fumarate,
1 g/kg emtricitabine, and 2 g/kg raltegravir. To deplete human NK
cells in vivo, mouse anti-human NKp46 antibodies (Cell Sciences,
clone B-L46) were administered by i.p. injection on day 0 and day
7 post infection. Each mouse received 50 μg antibody per injection.
Control mice received 100 μL PBS by i.p. injection. For bNab treatment, PGT121 or PGT121GRLR was administered by retroorbital injection. Each mouse received 250 μg antibody per injection. Control
mice received 100 μl PBS by retroorbital injection.
Functional analysis of NK cells and CD8+ T cells from humanized
mice. Spleens, livers, and submandibular, axillary, and thoracic LNs
were excised from mice and filtered through 100 μm strainers using
the back end of a syringe. The strainer was washed with tissue buffer
made of PBS with FBS. Samples were centrifuged followed by resuspension of the pellet in tissue buffer. For livers, cells were resuspended
in 8 mL of tissue buffer and 5 mL of 100% percoll and then centrifuged
for 20 minutes at 760g. Lungs were excised and cut into small pieces
with scissors. They were then incubated at 37°C with digestion buffer
contained collagenase and DNase I for 45 minutes. Samples were then
filtered through 100 μm strainers using the back end of a syringe. The
strainer was washed with tissue buffer. Samples were centrifuged followed by resuspension of pellet in 10 mL of 40% percoll. Samples were
centrifuged for 20 minutes at 760g. After single-cell suspensions from
all tissues were obtained, cells were utilized for 3 purposes, including
ICR staining, intracellular cytokine staining, and target cell lysis. ICR
staining was performed using freshly isolated cells. For intracellular
cytokine production, cells were stimulated with PMA (50 ng/mL) and
ionomycin (500 ng/mL) and stained with anti-CD107a antibody for
4 hours. Brefeldin A and monensin (golgiplug) were used for the final
hour of stimulation. Cells were then washed and stained with CD56,
CD3, CD8, NKp44, and CD16. Cytofix/Cytoperm kit (BD Biosciences)
was then utilized and intracellular staining was performed with IFN-γ,
TNF-α and GZMB (Supplemental Figure 11). Purified NK cells were
used to assess target cell lysis. To purify NK cells from mice, single cell
suspensions were obtained from specified organs as outlined above
followed by elimination of CD45+ mouse cells with EasySep Mouse
CD45 Positive Selection Kit (Stemcell Technologies) followed by
NK cell isolation using EasySep Human NK Cell Isolation Kit (Stemcell Technologies). Purified NK cells were coincubated with CFSElabeled (Thermo Fisher Scientific) K562 cells (ATCC), with effector-totarget ratios of 1:2, for 4 hours, and cytotoxicity was assayed by 7-AAD
uptake. Background spontaneous K562 blast death (measured via the
no effector control wells) was subtracted from the total to yield the
percentage of K562 cell–specific cytotoxicity. For experiments investigating perforin-mediated killing, concanamycin A (Sigma-Aldrich)
was utilized at 100 nM with cells incubated for 120 minutes prior to
the killing assay. To determine lysis of HIV-1–infected target cells, NK
cells and CD4+ T cells were purified separately from mice engrafted
with CD34+ cells from the same cord blood donor. Purified CD4+ T
cells were infected with the HIV-1 reporter virus NL4-3-ΔEnv-EGFP
for 3 days. Infected cells were then cocultured with freshly isolated NK
cells from various tissues in a 1:1 effector-to-target ratio for 4 hours
and cytotoxicity was assayed by 7-AAD uptake in GFP+ cells.
Flow cytometry analysis. Flow cytometry was performed using BD
LSRFortessa or BD Canto II and data were analyzed by Flowjo software.
Antibodies used for surface and intracellular staining were purchased
from Biolegend and include mCD45 (clone 30-F11), hCD45 (clone
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HI30), hCD3 (clone HIT3a), hCD4 (clone OKT4), hCD8 (clones HIT8a
and RPA-T8), hCD14 (clone M5E2), hNKp46 (clone 9E2), hCD56
(clone HCD56), hCD16 (clone 3G8). Antibodies purchased from eBioscience include hCD3 (clone UCHT1), hCD16 (clone CB16), from Beckman Coulter include anti-HIV-1 p24 (clone KC57-RD1), and from NIH
AIDS Reagent Program include anti-HIV-1 p24 (clone KC57). Additional antibodies were purchased from BD Biosciences and include hCD56
(clone NCAM16.2), hCD3 (clone SK7), hCD107a (clone H4A3), hIFN-γ
(clone 4S.B3), hTNF-α (clone mAB11), and 7AAD (51-2359KC) from BD
Pharmingen, and hGranzymeB (clone GB12) from Invitrogen.
Statistics. Data shown are mean values with error bars denoting
SEM. In figures comparing 2 groups, P values were calculated using
unpaired, 2-tailed t tests. When more than 2 groups were compared,
1-way ANOVA was utilized with Tukey’s multiple comparison post
test. In figures comparing multiple groups with multiple outcomes or
organs, P values were calculated using 1-way ANOVA with Tukey’s
multiple comparison post test, or 2-way ANOVA with Šidák’s multiple
comparison test or Tukey’s multiple comparison post test. Analysis
was performed with GraphPad Prism 8 (Graphpad Software). A P value less than 0.05 was consider significant.
Study approval. All animal experiments were approved by the
Institutional Animal Care and Use Committee of Washington University School of Medicine, approval no. 20-0224. Human cord blood
and tonsil samples were classified as surgical waste with no identifiers
attached and did not require further approval for usage.
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